Business Description
Iterum Therapeutics PLC
ISIN : IE000TTOOBX0
Total Employee Number:
9Description
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | -0.23 | |||||
Debt-to-Equity | -4.57 | |||||
Debt-to-EBITDA | -1.45 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -23.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 46.1 | |||||
3-Year EPS without NRI Growth Rate | 18.7 | |||||
3-Year FCF Growth Rate | -0.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.21 | |||||
9-Day RSI | 38.33 | |||||
14-Day RSI | 41.55 | |||||
3-1 Month Momentum % | 85.19 | |||||
6-1 Month Momentum % | -87.58 | |||||
12-1 Month Momentum % | -95.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.13 | |||||
Quick Ratio | 1.96 | |||||
Cash Ratio | 1.71 | |||||
Days Inventory | 332.97 | |||||
Days Sales Outstanding | 419.28 | |||||
Days Payable | 248.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.6 | |||||
Shareholder Yield % | -1539.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -146.41 | |||||
Operating Margin % | -5292.31 | |||||
Net Margin % | -6913.08 | |||||
EBITDA Margin % | -5949.74 | |||||
FCF Margin % | -5007.18 | |||||
OCF Margin % | -5003.59 | |||||
ROA % | -84.25 | |||||
ROIC % | -95.87 | |||||
3-Year ROIIC % | 37.46 | |||||
ROC (Joel Greenblatt) % | -121386.14 | |||||
ROCE % | -113.4 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.88 | |||||
EV-to-EBIT | -0.98 | |||||
EV-to-Forward-EBIT | -1.49 | |||||
EV-to-EBITDA | -1.04 | |||||
EV-to-Forward-EBITDA | -1.49 | |||||
EV-to-Revenue | 61.84 | |||||
EV-to-Forward-Revenue | 2.41 | |||||
EV-to-FCF | -1.24 | |||||
Earnings Yield (Greenblatt) % | -102.04 | |||||
FCF Yield % | -1408.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ITRMF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Iterum Therapeutics PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.39 | ||
| EPS (TTM) ($) | -0.75 | ||
| Beta | 6.7257 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.12 | ||
| Volatility % | 203.96 | ||
| 14-Day RSI | 41.55 | ||
| 14-Day ATR ($) | 0.017102 | ||
| 20-Day SMA ($) | 0.04378 | ||
| 12-1 Month Momentum % | -95.92 | ||
| 52-Week Range ($) | 0.005 - 0.9997 | ||
| Shares Outstanding (Mil) | 53.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Iterum Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Iterum Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| General meeting for 2026 | 2026-09-10 10:00 | In 57 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 20 days | ||
| First quarter earnings conference call for 2026 | 2026-07-24 | In 8 days | ||
| First quarter earnings results for 2026 | 2026-07-24 | In 8 days | ||
| Annual report for 2025 | 2026-07-17 | In 1 day | ||
| Third quarter earnings conference call for 2025 | 2025-11-14 08:30 | 0.56 (-6.29%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.56 (-6.29%) |
Show
Entries
Iterum Therapeutics PLC Frequently Asked Questions
What is Iterum Therapeutics PLC(ITRMF)'s stock price today?
The current price of ITRMF is $0.03. The 52 week high of ITRMF is $1.00 and 52 week low is $0.01.
When is next earnings date of Iterum Therapeutics PLC(ITRMF)?
The next earnings date of Iterum Therapeutics PLC(ITRMF) is 2026-07-24 Est..
Does Iterum Therapeutics PLC(ITRMF) pay dividends? If so, how much?
Iterum Therapeutics PLC(ITRMF) does not pay dividend.
Guru Commentaries on OTCPK:ITRMF
No articles.
Press Release
Articles on Iterum Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers